AIkido Pharma Inc. [NASDAQ: AIKI] closed the trading session at $0.58 on 10/28/20. The day’s price range saw the stock hit a low of $0.51, while the highest price level was $0.6196. The company report on October 28, 2020 that AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC.
Synthesis of Critical Chemical Intermediate for Drug Confirmed.
AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today provided an update on its preclinical work on its next-generation chemotherapeutic, DHA-dFdC, and the solid lipid nanoparticle (SLN) drug delivery system to treat pancreatic cancer, which the Company has licensed from the University of Texas at Austin.
The stocks have a year to date performance of -55.58 percent and weekly performance of -3.61 percent. The stock has been moved at -18.45 percent over the last six months. The stock has performed -4.90 percent around the most recent 30 days and changed -49.57 percent over the most recent 3-months.
If compared to the average trading volume of 1.84M shares, AIKI reached to a volume of 3674094 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about AIkido Pharma Inc. [AIKI]:
The Average True Range (ATR) for AIkido Pharma Inc. is set at 0.05, with the Price to Sales ratio for AIKI stock in the period of the last 12 months amounting to 2247.82. The Price to Book ratio for the last quarter was 0.60, with the Price to Cash per share for the same quarter was set at 0.83.
AIKI stock trade performance evaluation
AIkido Pharma Inc. [AIKI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.61. With this latest performance, AIKI shares dropped by -4.90% in over the last four-week period, additionally sinking by -18.45% over the last 6 months – not to mention a drop of -53.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIKI stock in for the last two-week period is set at 48.17, with the RSI for the last a single of trading hit 49.61, and the three-weeks RSI is set at 45.14 for AIkido Pharma Inc. [AIKI]. The present Moving Average for the last 50 days of trading for this stock 0.6056, while it was recorded at 0.5691 for the last single week of trading, and 0.8488 for the last 200 days.
AIkido Pharma Inc. [AIKI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AIkido Pharma Inc. [AIKI] shares currently have an operating margin of -63166.67. AIkido Pharma Inc.’s Net Margin is presently recorded at -46477.78.
Return on Total Capital for AIKI is now -50.24, given the latest momentum, and Return on Invested Capital for the company is -36.97. Return on Equity for this stock declined to -36.97, with Return on Assets sitting at -34.10.
Reflecting on the efficiency of the workforce at the company, AIkido Pharma Inc. [AIKI] managed to generate an average of -$1,394,333 per employee.AIkido Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 30.20 and a Current Ratio set at 30.20.
AIkido Pharma Inc. [AIKI]: Insider Ownership positions
There are presently around $0 million, or 13.30% of AIKI stock, in the hands of institutional investors. The top three institutional holders of AIKI stocks are: SABBY MANAGEMENT, LLC with ownership of 342,121, which is approximately New of the company’s market cap and around 5.64% of the total institutional ownership; UBS GROUP AG, holding 101,063 shares of the stock with an approximate value of $59000.0 in AIKI stocks shares; and VIRTU FINANCIAL LLC, currently with $49000.0 in AIKI stock with ownership of nearly New of the company’s market capitalization.
Positions in AIkido Pharma Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 8 institutional holders increased their position in AIkido Pharma Inc. [NASDAQ:AIKI] by around 594,608 shares. Additionally, 13 investors decreased positions by around 304,974 shares, while 4 investors held positions by with 261,110 shares. The mentioned changes placed institutional holdings at 638,472 shares, according to the latest SEC report filing. AIKI stock had 8 new institutional investments in for a total of 594,608 shares, while 9 institutional investors sold positions of 296,586 shares during the same period.